Skip to main content

Advertisement

Table 5 Health-related quality of life scores by erythropoiesis stimulating agent/supplemental iron use in patients with CKD stages 3 and 4 and those on dialysis

From: Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia

Subscales of the KDQOL-36 No ESA/supplemental iron use
Mean (SD)
ESA and/or supplemental iron use
Mean (SD)
P-value
Symptoms/problems list 83.5 (17.1) 77.1 (17.6) <0.0001
Effect of Kidney Disease 76.9 (19.0) 64.5 (21.0) <0.0001
Burden of Kidney Disease 61.5 (25.8) 46.9 (25.8) <0.0001
SF-12 physical composite summary 42.4 (10.1) 37.6 (9.5) <0.0001
 CKD stage 3 44.6 (9.3) 40.8 (9.9) 0.0019
 CKD stage 4 40.5 (10.3) 36.9 (8.9) 0.0007
 Dialysis 39.0 (10.4) 37.1 (9.7) 0.1441
SF-12 mental composite summary 47.9 (9.3) 45.4 (10.1) <0.0001
 CKD stage 3 49.7 (8.6) 46.9 (10.0) 0.0206
 CKD stage 4 46.9 (9.4) 44.9 (9.8) 0.0653
 Dialysis 44.3 (10.0) 45.3 (10.3) 0.4347
  1. Abbreviations: CKD chronic kidney disease, ESA erythropoiesis stimulating agent, KDQOL-36 Kidney Disease Quality of Life Instrument, SD standard deviation, SF-12 12-Item Short Form Health Survey